NUT MIDLINE CARCINOMA

This adverse event was reported 6 times

NUT MIDLINE CARCINOMA is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 TALIMOGENE LAHERPAREPVEC 1 0.0006
1 VORINOSTAT 1 0.0005
2 IFOSFAMIDE FOR INJECTION 2 0.0001
3 ETOPOSIDE 3 0.0000
4 PACLITAXEL 4 0.0000
5 ZOLEDRONIC ACID 1 0.0000
6 CARBOPLATIN 3 0.0000
7 DOXORUBICIN 2 0.0000
8 GEMCITABINE HYDROCHLORIDE 1 0.0000
9 CYCLOPHOSPHAMIDE FOR INJECTION 3 0.0000
See all drugs enriched for association with NUT MIDLINE CARCINOMA

NUT MIDLINE CARCINOMA is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Histone Deacetylase Inhibitor [EPC] 1 0.0003
1 Topoisomerase Inhibitor [EPC] 3 0.0000
2 Microtubule Inhibitor [EPC] 4 0.0000
3 HER2/neu Receptor Antagonist [EPC] 1 0.0000
4 Alkylating Drug [EPC] 3 0.0000
5 Platinum-based Drug [EPC] 3 0.0000
See all drug classes enriched for association with NUT MIDLINE CARCINOMA